Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study
GLP-1RAs and DPP-4Is were not associated with a significantly increased risk of CCA. GLP-1RAs even showed a reduced risk of CCA development. They can be considered as safe and effective treatment options for patients with T2DM at risk of CCA.
Authors
- Saleh A. Alqahtani (ORCID: https://orcid.org/0000-0003-2017-3526)
- Declan Walsh (ORCID: https://orcid.org/0000-0002-9310-1729)
- Carolin Victoria Schneider (ORCID: https://orcid.org/0000-0002-6728-9246)
- Winfield Scott Butsch (ORCID: https://orcid.org/0000-0001-7137-9423)
- Ezequiel Mauro (ORCID: https://orcid.org/0000-0002-0757-7676)
- Alejandro Forner (ORCID: https://orcid.org/0000-0002-9014-4950)
- Arunkumar Krishnan (ORCID: https://orcid.org/0000-0002-9452-7377)
- Hendrik‐Tobias Arkenau (ORCID: https://orcid.org/0000-0003-0372-0540)
Institutions
- Cleveland Clinic (US)
- Sarah Cannon Research Institute (GB)
- Cornell University (US)
- King Faisal Specialist Hospital & Research Centre (SA)
- Levine Cancer Institute (US)
- Hospital Clínic de Barcelona (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Weill Cornell Medicine (US)
- University College London (GB)
- Wake Forest University (US)
- Universitat de Barcelona (ES)
- RWTH Aachen University (DE)
Publication Details
- Journal
- Journal of Clinical & Translational Endocrinology
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1016/j.jcte.2024.100370
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.07